Skip to main content

Market Overview

Aveo Pharma's Tivozanib To Be Tested In Combination With Opdivo In Kidney Cancer

Share:

AVEO Pharmaceuticals Inc (NASDAQ: AVEO) has entered into a collaboration and supply agreement with Bristol-Myers Squibb Co (NYSE: BMY) to evaluate the former's Fotivda (tivozanib) in combination with the latter's Opdivo (nivolumab).

  • The Phase 3 TiNivo-2 trial will enroll around 326 patients with advanced relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.
  • The study's primary endpoint will assess progression-free survival, with key secondary endpoints to include overall survival, overall response rate and duration of response, and safety.
  • Bristol Myers Squibb will supply Opdivo supply for the study. AVEO will serve as the study sponsor and will be responsible for costs associated with the trial execution.
  • Yesterday, the company completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital Inc.
  • This second tranche was made available in connection with the recent FDA approval for Fotivda in relapsed or refractory renal cell carcinoma for patients who have received two or more prior systemic therapies.
  • Price Action: AVEO shares are up 7.8% at $12.8 in premarket trading on the last check Friday.
 

Related Articles (BMY + AVEO)

View Comments and Join the Discussion!

Posted-In: Kidney CancerBiotech News Health Care Contracts Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com